Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, fidaxomicin (Dificlir®) cannot be endorsed for use within NHS Wales for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in paediatric patients from birth to < 18 years of age. Consideration should be given to official guidelines on the appropriate use of antibacterial agents. Please refer to the AWMSG position statement on the appraisal of antimicrobial medicines |
||
|
||
Medicine details |
||
| Medicine name | fidaxomicin (Dificlir®) | |
| Formulation | 200 mg film-coated tablet | |
| Reference number | 2076 | |
| Indication | Treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in paediatric patients from birth to < 18 years of age. Consideration should be given to official guidelines on the appropriate use of antibacterial agents |
|
| Company | Tillotts Pharma UK Ltd | |
| BNF chapter | Infections | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 24/06/2021 | |
| Further information AWMSG position statement on the appraisal of antimicrobial medicines |
||